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A 54-year-old woman presented with a mass in the right breast and right thigh; her condition was diagnosed as 
multiple myeloma (light chain, lambda type; serum M protein level 1,730 mg/dL) with plasmacytomas. Plasmacytomas 
showed high radiolabeled fluorodeoxyglucose in positron emission tomography (Figs. A, C, E, G). The patient showed 
partial response (serum M protein level decreased to 183 mg/dL) after 2 cycles of vincristine, adriamycin, and dex-
amethaxone (VAD) chemotherapy. After additional 4 cycles of chemotherapy with bortezomib, cyclophosphamide, 
thalidomide, dexamethaxone (vel-CTD; Kim et al. Ann Hematol 2010), plasmacytomas completely disappeared (Figs. 
B, D, F, H). The patient was considered to have achieved complete remission (CR) on the basis of normal range 
and ratio of kappa and lambda chains in free light chain assay, absence of monoclonal band in immunoelectropho-
resis, and presence of less than 5% plasma cells in the bone marrow aspirate. The patient was treated with a high 
dose of melphalan (200 mg/m
2) followed by autologous peripheral blood stem cell transplantation, and received main-
tenance therapy with thalidomide and dexamethasone (TD); the patient continues to remain in CR even 11 months 
after the treatment.